Form 8-K - Current report:
SEC Accession No. 0000939767-25-000004
Filing Date
2025-01-13
Accepted
2025-01-13 16:34:27
Documents
16
Period of Report
2025-01-12
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K exel-20250112.htm   iXBRL 8-K 26798
2 EX-99.1 exel20250112exhibit991.htm EX-99.1 64335
6 GRAPHIC exel-20250112_g1.jpg GRAPHIC 55431
7 GRAPHIC exelixis_logoxrgbx2023a.jpg GRAPHIC 55431
  Complete submission text file 0000939767-25-000004.txt   438847

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT exel-20250112.xsd EX-101.SCH 1798
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT exel-20250112_lab.xml EX-101.LAB 21885
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT exel-20250112_pre.xml EX-101.PRE 12522
18 EXTRACTED XBRL INSTANCE DOCUMENT exel-20250112_htm.xml XML 2709
Mailing Address 1851 HARBOR BAY PARKWAY ALAMEDA CA 94502
Business Address 1851 HARBOR BAY PARKWAY ALAMEDA CA 94502 6508377000
EXELIXIS, INC. (Filer) CIK: 0000939767 (see all company filings)

EIN.: 043257395 | State of Incorp.: DE | Fiscal Year End: 0103
Type: 8-K | Act: 34 | File No.: 000-30235 | Film No.: 25526740
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)